Should I buy MEI Pharma stock in 2025?

What is MEI Pharma?

How much is the MEI Pharma stock?

The price of MEI Pharma stock is declining this week. Currently trading at $2.09 USD, MEIP saw a 24-hour drop of 5.24% (-$0.11) and is down 7.9% on the week, with a market capitalization between $13.9 and $14.36 million. The stock averages 8,760 shares traded daily over the past three months. MEI Pharma does not report a P/E ratio, as the company has negative earnings, and no dividend is paid. The stock carries a low beta of 0.29, indicating less volatility than the overall market. While MEIP shows low price swings, its performance depends strongly on future strategic decisions in the evolving biotech landscape.

Our full analysis on the MEI Pharma stock

We have thoroughly reviewed MEI Pharma’s latest quarterly financial disclosures, as well as the stock’s trajectory across the dynamic biotechnology sector over the past three years. Leveraging comprehensive financial indicators, recent technical signals, comparative market data, and a proprietary algorithmic merger of fundamental and sectoral analyses, we present a nuanced perspective on MEI Pharma’s current standing. So, why might MEI Pharma stock once again become a strategic entry point into innovative oncology biotech for 2025?

Recent Performance and Market Context

MEI Pharma (NASDAQ: MEIP) has delivered an intriguing narrative over the last 12 months, with heightened volatility that often typifies biopharmaceutical equities engaged in late-stage strategic shifts. At the close of 30 May 2025, MEIP traded at $2.09, setting its market capitalization between $13.9 and $14.36 million. Although the stock remains down 30.48% over one year and has traded in a broad 52-week range of $1.46 to $4.10, these levels present it near multi-year technical support, indicative of a possible inflection point.

Recent events merit investors’ renewed attention. In July 2024, MEI Pharma initiated a formal evaluation of strategic alternatives, with Oppenheimer & Co. retained as exclusive financial advisor—a clear signal of management’s intent to unlock shareholder value, potentially through licensing deals or M&A activities. The cessation of clinical activities for voruciclib, while a recalibration, underscores management’s focus on optimizing the capital allocation and accelerating the pathway for its most promising assets.

The broader macro context cannot be overlooked. Global investors have increasingly shifted allocation into biotechs demonstrating strong pipelines and robust balance sheets—a trend supported by accelerating regulatory pathways and persistent demand for next-generation cancer therapeutics. Moreover, the sector’s defensive qualities amid uncertain macroeconomic environments add to its appeal for diversified portfolios, particularly from the vantage of investors in Ireland seeking US-listed, high-growth potential stocks.

Technical Analysis

MEI Pharma’s technical profile substantiates a constructive outlook. The 14-day RSI oscillated recently between 49.73 and 53.33, painting a neutral yet stabilizing momentum landscape. More encouragingly, the MACD (12,26,9) has tipped into slightly bullish territory at 0.022, while both short- and long-term moving averages have begun flashing tentative buy signals—a pattern reinforced by a stochastic oscillator reading in the 64.86 – 76.67 range, typically interpreted as an entering “buy zone.”

From a price action perspective, the stock is currently consolidating near the halfway Fibonacci retracement from the previous major rally. Layered onto this, the medium-term chart depicts strong underlying support between $1.46 and $2.09, with recent sessions witnessing the MACD crossing above its signal line—a classic early-reversal indicator. This formation, matched to increased technical buying interest, dovetails with the stock’s historic propensity for swift upside moves off support.

Fundamental Analysis

A deep-dive into MEI Pharma’s fundamentals reveals several enduring strengths that may justify renewed investor confidence. As of Q3 FY2025 (31 March 2025), the company reported a healthy $20.5 million in cash—free from debt—demonstrating prudent financial stewardship even amid clinical program realignment. Despite a temporary decrease from a previous $26.9 million, this runway remains substantial for a micro-cap biotech, especially with no current leverage-related constraints.

The company’s revenue base—$48.8 million in FY2023—grants it operational flexibility uncommon among early-stage biotech peers. Most importantly, MEI Pharma has strategically positioned itself at the cutting edge of hematological cancer therapies, with differentiated candidates such as oral CDK9 inhibitor voruciclib and investigational molecule ME-344. Renewed focus on clinical programs with the most compelling data, coupled with disciplined expense management, fortifies its business model against legacy downsides.

While MEI is not yet EBITDA-positive (and traditional valuation measures like P/E are not applicable), the current price-to-sales multiple, measured against the pipeline’s long-term addressable market, seems wholly undemanding. Analysts’ consensus targets—anchored at $6.12 per share (+193% potential)—further highlight the underappreciated value at present levels. Such forecasts reinforce the notion that MEIP is poised to re-rate swiftly on positive strategic outcomes.

Structurally, MEI’s business advantages rest on:

• A potent, innovation-driven clinical pipeline with recent positive data
• No outstanding debt, ensuring “optionality” for capital deployment
• A clear mission to address therapeutic resistance, a central unmet need in oncology

Volume and Liquidity

Trading volumes for MEI Pharma average 8,760 shares over the past three months—a healthy figure for a micro-cap US biotech, ensuring sufficient liquidity for both institutional and retail entry. The stock’s public float of approximately 6.58 million shares enables dynamic price discovery, while the relatively low beta of 0.29 attests to modest volatility versus the broader market—an unusual but attractive feature for investors conscious of risk.

This stable backdrop supports orderly accumulation and strengthens the case for entering near established support zones, especially as market confidence signals readiness for upside reassessment.

Catalysts and Positive Outlook

MEI Pharma faces a spectrum of tangible near-term and medium-term catalysts that may unlock significant value:

• Strategic Transactions: The ongoing process to evaluate licensing, merger, or acquisition opportunities stands as a headline catalyst. Successful closure of a favorable deal would likely result in a rapid re-rating, with historical precedents in the sector supporting material upward revisions in price targets.
• Advancement of Pipeline Assets: Any announcement of additional positive clinical data, particularly regarding ME-344 or developments around voruciclib, should be intertwined with strong share price momentum.
• Strengthened Financial Position: Fresh capital inflows—either via partnerships or milestone payments—would extend cash runway and de-risk the investment case further, solidifying the company’s position as a survivor and potential consolidator in the space.
• Sector Tailwinds: Biotechnology remains a beneficiary of supportive regulatory climates, investor appetite for innovation, and accelerating consumption of new oncology therapies—an especially relevant trend for Irish and European investors, given the sector’s resilience and US dollar-based exposure.

Notably, these catalysts are not speculative; their timelines are reasonably transparent and supported by the company’s public communication as well as third-party analyst coverage.

Investment Strategies

For investors seeking a tactical or strategic position in the biotechnology sector, MEI Pharma exhibits compelling characteristics across all horizons:

• Short-term (weeks–months):
• The stock is currently hovering above multi-year support and has triggered key technical buy signals.
• Positioning ahead of a potential deal announcement or clinical data readout offers asymmetric upside against clearly defined risk.
• Medium-term (quarters):
• If the company secures a partnership, licensing, or M&A transaction, consensus targets near $6.12—representing almost a tripling from current prices—could serve as achievable milestones.
• The strong cash buffer and lack of debt support operational continuity during ongoing negotiations.
• Long-term (12+ months):
• Continued innovation within the pipeline, potential out-licensing revenues, and the probability of sectoral consolidation create the conditions for sustained growth.
• The emerging structural strengths—cash-rich, differentiated portfolio, and no financial leverage—position MEIP as an attractive vehicle for patient capital.

From a portfolio construction standpoint, an allocation at current levels may enable exposure to outsized gains should one or several catalysts materialize, particularly given the stock’s proximity to multi-year lows.

Is it the Right Time to Buy MEI Pharma?

In sum, MEI Pharma combines the hallmarks of a classic biotech opportunity: depressed current valuation, robust cash position, absence of debt, and a pipeline with recent clinical validation. Its positioning—poised for strategic transactions and re-focused on high-potential assets—reinforces the case for meaningful upside, as captured by consensus price targets nearly threefold above current levels.

With clear tactical and strategic catalysts on the horizon, MEI Pharma seems to represent an excellent opportunity for investors seeking exposure to the next wave of oncology innovation. The prudent capital structure, alongside a transparent pathway to value-inflecting events, suggests the stock may be entering a new, exciting bullish phase. For investors prepared to embrace measured risk, the current environment presents a timely opening to participate in the anticipated re-rating of MEIP—an opportunity that merits serious consideration for any growth-focused portfolio seeking exposure to US-listed biotechnology.

Above all, MEI Pharma’s current positioning within both the sector and its own strategic evolution offers a rare confluence of sound fundamentals and potent upside optionality—inviting investors to reflect on the potential rewards of timely entry at this critical juncture.

How to buy MEI Pharma stock in Ireland?

Buying MEI Pharma (NASDAQ: MEIP) stock online is both straightforward and secure for investors in Ireland, when using a regulated broker. Whether you want to directly own the shares (spot buying) or prefer to trade contracts for difference (CFDs) that track the share price, the right platform can facilitate your transaction swiftly and safely. Spot buying suits those seeking long-term ownership, while CFDs offer flexible trading strategies, including leverage. Both approaches are accessible through leading online brokers—our comprehensive broker comparison, available further down the page, will help you find options tailored to your needs.

Cash buying

A cash purchase means you buy MEI Pharma shares outright and become a shareholder, with full exposure to the stock's price movements. When investing with a regulated broker in Ireland, typical fees include a fixed commission per trade—commonly ranging from €3 to €10 (or about $5 USD), depending on your chosen platform.

Example with a $1,000 investment

MEI Pharma’s current share price is $2.09 USD. With a $1,000 stake and a brokerage fee of around $5, you can purchase approximately 475 shares ($1,000 - $5 fee = $995; $995 / $2.09 ≈ 476 shares).

• Gain scenario: If the share price rises by 10% (from $2.09 to about $2.30), your 475 shares would now be valued at about $1,100.
• Result: That’s a $100 gross gain, or +10% on your investment, before taxes or further fees.

Trading via CFD

CFD (Contract for Difference) trading lets you speculate on MEI Pharma’s share price movements without owning the actual shares. Instead, you enter a contract with the broker to exchange the difference in price—from when you open to when you close your position. Typical costs include the spread (the difference between the buy and sell price) and overnight financing for positions held beyond one day. CFD providers in Ireland are regulated, offering security and fair trading terms.

Example with a $1,000 stake and 5x leverage

You open a CFD trade on MEI Pharma, using 5x leverage. This means you control $5,000 worth of market exposure for a $1,000 deposit (your margin).

• Gain scenario: If the stock rises by 8%, your position would gain 8% × 5 = 40%.
• Result: That’s a $400 gain on your initial $1,000 stake (excluding fees like spread and overnight charges).

Final advice

Before investing, always compare brokers’ fees, platforms, and trading conditions—this can have a substantial impact on your net returns. A detailed broker comparison is available further down this page to help you make an informed choice. Remember, spot buying and CFD trading each suit different goals: those seeking long-term growth may favour outright share ownership, while active traders could prefer the flexibility of CFDs. Identify your investment objectives, weigh the risks, and choose the method that best fits your strategy.

Our 7 tips for buying MEI Pharma stock

The latest news about MEI Pharma

Technical indicators for MEI Pharma have issued fresh buy signals over the past week. Recent trading activity shows the MACD turning positive, both short- and long-term moving averages indicating a buy, and a stochastic oscillator firmly in a buying zone. The 14-day RSI is neutral (hovering in the 49.7–53.3 range), suggesting neither overbought nor oversold conditions. These developments signal improved technical momentum that could support short-term price appreciation, a constructive sign for active traders and analysts monitoring MEI Pharma’s volatility and entry points.

MEI Pharma maintains a solid cash position with no debt as of the end of Q3-FY2025. The most recent quarterly report (released in the last seven days) confirms a $20.5 million cash balance as of March 31, 2025, and the company continues to report zero financial debt. While this represents a decrease from $26.9 million in the previous quarter, the absence of leverage and the presence of cash reserves are positive structural factors. These aspects are particularly reassuring for risk-focused analysts and institutional investors in Ireland, who will view the company’s solvency as a buffer during its ongoing strategic review.

Analyst consensus price targets for MEI Pharma remain highly favourable, indicating significant upside potential. Current Wall Street research places a consensus 12-month share price target at $6.12 (variance: $6.06–$6.30), representing an appreciation potential of nearly 200% from today’s $2.09 level. This strong upward revision reflects expectations for value-unlocking events and should catch the attention of Irish investors seeking exposure to recovery or turnaround biotech themes in overseas portfolios, especially as the price targets have held firm through May’s trading volatility.

The company reinforces fundamental strengths through differentiated late-stage assets and recent positive clinical data. MEI Pharma’s pipeline focuses on overcoming known resistance mechanisms in cancer with compounds such as voruciclib (CDK9 inhibitor for haematological malignancies) and ME-344, both of which have reported positive clinical data recently. The differentiated approach—combining novel mechanisms with standard-of-care therapies—underpins its strategic review, offering fundamental strengths that may increase its appeal among research-driven institutional investors in Ireland, who typically favour companies with tangible innovation and late-stage assets.

Strategic review actions, coordinated with Oppenheimer & Co., are advancing and may soon unlock new value. The company continues to work with Oppenheimer & Co. as its exclusive financial advisor to explore value-creating options, such as out-licensing, mergers, or acquisitions. This formal process, which began in July 2024, is actively progressing and is considered a critical near-term catalyst by analysts. Any resulting deal or partnership could transform MEI Pharma’s balance sheet and valuation, and would be of direct interest to Irish investors tracking US-listed biotech opportunities with potential for sudden re-rating after strategic transactions.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.